Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial

Mohler, 2010, NCCN clinical practice guidelines in oncology: prostate cancer, J Natl Compr Canc Netw, 8, 162, 10.6004/jnccn.2010.0012 Dearnaley, 1999, Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial, Lancet, 353, 267, 10.1016/S0140-6736(98)05180-0 Dearnaley, 2012, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial, Lancet Oncol, 13, 43, 10.1016/S1470-2045(11)70293-5 Creak, 2013, Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up, Br J Cancer, 109, 651, 10.1038/bjc.2013.394 Kuban, 2008, Long-term results of the M D Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 70, 67, 10.1016/j.ijrobp.2007.06.054 Dearnaley, 2007, Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial, Lancet Oncol, 8, 475, 10.1016/S1470-2045(07)70143-2 Zietman, 2010, Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09, J Clin Oncol, 28, 1106, 10.1200/JCO.2009.25.8475 Heemsbergen, 2013, Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival, Radiother Oncol Beckendorf, 2011, 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial, Int J Radiat Oncol Biol Phys, 80, 1056, 10.1016/j.ijrobp.2010.03.049 Denham, 2011, Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial, Lancet Oncol, 12, 451, 10.1016/S1470-2045(11)70063-8 D'Amico, 2008, Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial, JAMA, 299, 289 Jones, 2011, Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med, 365, 107, 10.1056/NEJMoa1012348 Roach, 2008, Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610, J Clin Oncol, 26, 585, 10.1200/JCO.2007.13.9881 Dearnaley, 2007, The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397), Radiother Oncol, 83, 31, 10.1016/j.radonc.2007.02.014 Syndikus, 2010, Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397), Int J Radiat Oncol Biol Phys, 77, 773, 10.1016/j.ijrobp.2009.05.052 Sydes, 2004, Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer, Radiother Oncol, 72, 199, 10.1016/j.radonc.2004.04.007 Roach, 1993, The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer, J Urol, 150, 1923, 10.1016/S0022-5347(17)35937-2 Pilepich, 1987, Correlation of radiotherapeutic parameters and treatment related morbidity—analysis of RTOG Study 77-06, Int J Radiat Oncol Biol Phys, 13, 1007, 10.1016/0360-3016(87)90038-1 1995, LENT SOMA scales for all anatomic sites, Int J Radiat Oncol Biol Phys, 31, 1049, 10.1016/0360-3016(95)90159-0 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Soc, 94, 496, 10.1080/01621459.1999.10474144 Crook, 2012, Intermittent androgen suppression for rising PSA level after radiotherapy, N Engl J Med, 367, 895, 10.1056/NEJMoa1201546 Al-Mamgani, 2008, Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 72, 980, 10.1016/j.ijrobp.2008.02.073 Wilt, 2012, Radical prostatectomy versus observation for localized prostate cancer, N Engl J Med, 367, 203, 10.1056/NEJMoa1113162 Bill-Axelson, 2011, Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 364, 1708, 10.1056/NEJMoa1011967 Klotz, 2012, Active surveillance: the Canadian experience with an “inclusive approach”, J Natl Cancer Inst Monogr, 45, 234, 10.1093/jncimonographs/lgs042 Roach, 2006, Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int J Radiat Oncol Biol Phys, 65, 965, 10.1016/j.ijrobp.2006.04.029 Fitch, 2006, Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation, Int J Radiat Oncol Biol Phys, 66, 1430, 10.1016/j.ijrobp.2006.03.024 Bria, 2009, Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials, Cancer, 115, 3446, 10.1002/cncr.24392 Shelley, 2009, A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma, Cancer Treat Rev, 35, 9, 10.1016/j.ctrv.2008.08.002 Zumsteg, 2013, Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy, Int J Radiat Oncol Biol Phys, 85, 1012, 10.1016/j.ijrobp.2012.07.2374 Castle, 2013, Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?, Int J Radiat Oncol Biol Phys, 85, 693, 10.1016/j.ijrobp.2012.06.030 Morris, 2013, Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer, Cancer, 119, 1537, 10.1002/cncr.27911 Crook, 2009, Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial, Cancer, 115, 673, 10.1002/cncr.24020 Zelefsky, 1998, Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer, Int J Radiat Oncol Biol Phys, 41, 491, 10.1016/S0360-3016(98)00091-1 Stephens, 2007, The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397), BJU Int, 99, 301, 10.1111/j.1464-410X.2006.06560.x Leibel, 1994, The biological basis and clinical application of three dimensional conformal external beam radiation therapy in carcinoma of the prostate, Semin Oncol, 21, 580 Sandler, 1995, Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients, Int J Radiat Oncol Biol Phys, 33, 797, 10.1016/0360-3016(95)00219-7 Pollack, 1996, Conventional vs. Conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity, Int J Radiat Oncol Biol Phys, 34, 555, 10.1016/0360-3016(95)02103-5 Spratt, 2013, Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 85, 686, 10.1016/j.ijrobp.2012.05.023 Zaorsky, 2014, High dose rate brachytherapy boost for prostate cancer: a systematic review, Cancer Treat Rev, 40, 414, 10.1016/j.ctrv.2013.10.006